Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
09 2022
Historique:
received: 16 02 2022
revised: 09 04 2022
accepted: 30 05 2022
pubmed: 15 6 2022
medline: 28 9 2022
entrez: 14 6 2022
Statut: ppublish

Résumé

To compare the therapeutic effect of Bacille Calmette-Guérin (BCG) intravesical instillation in older and younger patients with high-risk non-muscle-invasive bladder cancer. The comparison was performed with propensity score matching (PSM) without terminating the death of the older patients using relatively large-scale retrospective data from multiple institutes in Japan. Overall, 3283 patients diagnosed with non-muscle-invasive bladder cancer treated with intravesical BCG instillation during 2000-2018 in 31 institutes were examined; 1437 and 602 patients with high-grade T1 and Tis tumors were divided into those aged ≥75 and <75 years. Multivariate analysis using the Fine-Gray competing risks regression model before PSM and survival analysis using the cumulative incidence method after PSM were performed. In the pre-PSM series of high-grade T1 tumors, age ≥75 years was an independent prognostic factor for both recurrence and progression in multivariate analysis (P = .015 and P = .013). In the pre-PSM series with Tis tumor, no variables to predict recurrence and progression was found. In the post-PSM series of 870 high-grade T1 tumors, cumulative probability of recurrence after BCG intravesical instillation were significantly higher in patients aged ≥75 years than in those aged <75 years (P = .008). The frequency of discontinuation of BCG instillation in patients aged ≥75 years with high-grade T1 and Tis was not significantly different from those in patients aged <75 years (P = .564 and P = .869). The cumulative probability of recurrence after intravesical BCG instillation was significantly higher in older than in younger patients with high-grade T1 bladder cancer.

Identifiants

pubmed: 35700751
pii: S0090-4295(22)00455-1
doi: 10.1016/j.urology.2022.05.034
pii:
doi:

Substances chimiques

Adjuvants, Immunologic 0
BCG Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-164

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Takamitsu Inoue (T)

Department of Renal and Urological Surgery, International University of Health and Welfare, Narita, Chiba, Japan; Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. Electronic address: takmitz@gmail.com.

Makito Miyake (M)

Department of Urology, Nara Medical University Graduate School of Medicine, Kashihara, Nara, Japan.

Nobutaka Nishimura (N)

Department of Urology, Nara Medical University Graduate School of Medicine, Kashihara, Nara, Japan.

Mizuki Onozawa (M)

Department of Renal and Urological Surgery, International University of Health and Welfare, Narita, Chiba, Japan.

Soki Kashima (S)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

Kazuyuki Numakura (K)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

Shintaro Narita (S)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

Kota Iida (K)

Department of Urology, Nara Medical University Graduate School of Medicine, Kashihara, Nara, Japan.

Motohide Uemura (M)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Yuto Matsushita (Y)

Department of Urology, Hamamatsu University Graduate School of Medicine, Hamamatsu, Shizuoka, Japan.

Junichi Inokuchi (J)

Department of Urology, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Yoshiyuki Matsui (Y)

Department of Urology, National Cancer Center Hospital, Tokyo, Japan.

Rikiya Taoka (R)

Department of Urology, Kagawa University Faculty of Medicine, Takamatsu, Kagawa, Japan.

Takahiro Kojima (T)

Department of Urology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.

Takashi Kobayashi (T)

Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Naotaka Nishiyama (N)

Department of Urology, University of Toyama Faculty of Medicine, Toyama, Japan.

Hiroshi Kitamura (H)

Department of Urology, University of Toyama Faculty of Medicine, Toyama, Japan.

Hiroyuki Nishiyama (H)

Department of Urology, University of Tsukuba Faculty of Medicine, Tsukuba, Ibaraki, Japan.

Kiyohide Fujimoto (K)

Department of Urology, Nara Medical University Graduate School of Medicine, Kashihara, Nara, Japan.

Tomonori Habuchi (T)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH